Synapse - Helena Yu

Results (292)

SRC family kinase inhibition targets YES1 and YAP1 as primary drivers of lung cancer and as mediators of acquired resistance to ALK and epidermal growth factor receptor inhibitors

Journal Article

Sato, H.; Kubota, D.; Qiao, H.; Jungbluth, A.; Rekhtman, N.; Schoenfeld, A. J.; Yu, H. A.; Riely, G. J.; Toyooka, S.; Lovly, C. M.; more...
JCO Precision Oncology (2022)

Fulltext@MSK | Save

AKT pathway as a therapeutic target to constrain lineage plasticity leading to histological transdifferentiation

Meeting Abstract

Quintanal-Villalonga, A.; Taniguchi, H.; Zhan, Y. A.; Uddin, F.; Allaj, V.; Manoj, P.; Shah, N. S.; Bhanot, U. K.; Egger, J.; Qiu, J.; more...
Cancer Research (2022)

Fulltext@MSK | Save

ORCHARD: Osimertinib plus necitumumab in patients (pts) with advanced NSCLC whose disease progressed on first-line (1L) osimertinib

Meeting Abstract

Riess, J. W.; De Langen, J. A.; Piotrowska, Z.; Goldberg, S. B.; Goldman, J. W.; Okamoto, I.; Aix, S. P.; Teraoka, S.; Ambrose, H.; Tang, K. H.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

HERTHENA-Lung02: A randomized phase III study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR TKI

Meeting Abstract

Mok, T. S. K.; Wu, Y. L.; Nishio, M.; Reck, M.; Wu, E.; Sternberg, D. W.; Esker, S.; Yu, H. A.
Annals of Oncology (2022)

Fulltext@MSK | Save

Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)

Meeting Abstract

Yu, H. A.; Cantero, F.; Kim, B.; Lee, M.; Wu, E.; Sternberg, D. W.; Jänne, P. A.
Annals of Oncology (2022)

Fulltext@MSK | Save

ORCHARD platform study: Osimertinib plus datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib

Meeting Abstract

De Langen, J.; Cho, B. C.; Piotrowska, Z.; Le, X.; Goldberg, S. B.; Goldman, J. W.; Okamoto, I.; Hewson, N.; Maidment, J.; Tang, K. H.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas

Journal Article

Selenica, P.; Marra, A.; Choudhury, N. J.; Gazzo, A.; Falcon, C. J.; Patel, J.; Pei, X.; Zhu, Y.; Ng, C. K. Y.; Curry, M.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20)

Meeting Abstract

Yu, H. A.; Tan, D. S. W.; Smit, E. F.; Spira, A. I.; Soo, R. A.; Nguyen, D.; Lee, V. H. F.; Yang, J. C. H.; Velcheti, V.; Wrangle, J. M.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Phase II randomized study comparing proton craniospinal irradiation with photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis